Loading...
XSTO
SPEC
Market cap7mUSD
Dec 05, Last price  
0.17SEK
1D
-2.91%
1Q
-0.95%
Jan 2017
-90.29%
IPO
-88.48%
Name

SpectraCure AB (publ)

Chart & Performance

D1W1MN
XSTO:SPEC chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
3.17%
Rev. gr., 5y
661.46%
Revenues
0k
-100.00%
1,490,125476,195778,500172,912258,953596,0007631,2110539,000318,0000
Net income
-23m
L+12.54%
-5,732,138-4,345,965-5,884,582-6,372,149-8,696,619-9,610,000-13,685,000-15,407,000-23,341,000-25,326,000-20,441,000-23,004,000
CFO
-22m
L+16.84%
0-604,491-9,714,363-19,596,2366,325,959-8,972,000-10,055,000-9,404,000-18,603,000-22,962,000-18,680,000-21,826,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.
IPO date
Jul 01, 2015
Employees
13
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT